Based on Latest Research, JZZ Technologies, Inc. Announces New Immune Boost and Anti-Inflammatory Products Developed Through Nutrific Inc.
New research from GenBio Inc. working with Nutrific Inc. is focused on the body's signaling process to address inflammatory disorders and its reaction to the Cytokine Storm
West Palm Beach, Florida--(Newsfile Corp. - December 22, 2021) - JZZ Technologies, Inc., (OTC Pink: JZZI) is advancing research being forwarded by its anticipated venture with Nutrific, Inc. and GenBio Inc. in order to provide a breakthrough immune boost and anti-inflammatory product line.
The new research focuses on the body's negative reaction to viruses, such as the SARS-2 virus among others. International research supports that this response is an unnatural reaction that should be treatable through immune boost and anti-inflammatory products.
The Nutrific products aim to specifically address the transduction (signaling) process in inflammatory disorders to mitigate the worst effects of a virus and the body's response to them.
These two areas represent massive markets where a relevant natural treatment could provide significant revenues through a patented treatment. The global immune health supplements market is projected to grow from $20.18 billion in 2021 to $31.50 billion in 2028 at a CAGR of 6.6% from 2021 to 2028 (source: Fortune Business Insights).Alongside the immune health market, the Global Anti-Inflammatory Therapeutics market size is estimated to grow at CAGR of almost 6% with USD 27.53 billion during the forecast period 2021-2024 (source: MarketWatch). These are the two markets that Nutrific expects to enter with its new products.
Based on GenBio Inc.'s own internal research in Australia with its CSO coordinating translational research, treatment must address the following factors:
- Certain viruses initiate a reaction from the immune system which thus creates an inflammatory response, including Cytokine Storm (CS)
- CS is an accelerated production of an array of pro-inflammatory cytokines
- CS then instigates different inflammatory pathways via their receptors on immune and tissue cells
- This creates a variety of symptoms. CS can be a life-threatening clinical condition in which the excessive overproduction of both inflammatory cytokines and excessive activation of immune cells leads to medical complications
- Current research focus by the GenBio team is on identifying natural extracts (and their key antioxidant molecules) than can reduce the intensity/severity of CS, particularly in the early stages. Particular attention will be paid to attempt to confine mechanisms of action to dampening specific immune pathways without impairing the host defense
- Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (e.g., obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19, but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders
Giles Tilley, CEO Of GenBio Inc., stated, "Significantly, these issues all attest to the immediate use of rare bioactive Australian natural extracts in the reduction of anti-inflammatory or anti thrombotic situations in a system wide occurrence in both healthy and overweight/obese populations."
"Metabolic dysfunction might lead to a baseline state of chronic inflammation, given that proinflammatory cytokines, such as TNFα, IL-6, and IL-1β, are upregulated in the adipose tissue of patients with metabolic syndrome," added Tilley.
As part of its efforts to keep pace with the significant expansion that its biotechnology and biosciences operations will create, JZZ Technologies Inc. is reviewing the potential for new corporate headquarters. Management is in discussions with several governmental and trade groups to establish the best, most flexible solution for the scaling of the company for the foreseeable future.
About GenBio Inc.
Based in Aliso Viejo, California, GenBio, Inc. (www.genbioinc.com) is an early-stage biotechnology company researching novel therapeutics from a variety of extracts. Based on recent US research, the company has created an Investigational New Drug (IND) research program from novel natural compounds that are highly effective as anti-inflammatory agents. CSO, Professor Lindsay Brown, is a renowned international researcher leading GenBio's product development and research. The company also has access to other global scientific teams that are investigating specific properties for the same new, disruptive molecular platforms for pain relief, anti-inflammation, and age-related healthcare issues.
About JZZ Technologies, Inc.
JZZ Technologies, Inc. is a diversified technology company engaged in the following two distinct business sectors: (i) its digital media business, which includes online media and apps (activelifestylemedia.com), content creation, digital marketing, streaming video content, publishing, and free over-the-air television (EyeOnTV) targeted to active adults 55+, and; (ii) strategic biotechnology and bioscience-related to Human Life Extension and Human Longevity that can be immediately leveraged to support improved quality of life for the senior population.
DISCLAIMER and FORWARD-LOOKING STATEMENTS
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; and other risks detailed in the Company's filings with the OTC Markets. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/108305